Jul 1, 2022 | News
SUGAR LAND, TX – (July 1, 2022) Subcutaneous immune globulin (IGSC) is indicated for the treatment of primary immunodeficiences (PID) and offers the convenience of self-administration, fewer systemic reactions, and more stable IgG levels compared to intravenous IG...
May 7, 2020 | News
SUGAR LAND, TX – (May 7, 2020) Healix Infusion Therapy is pleased to announce that its collaborative research study regarding Immune Globulin Subcutaneous 16.5% (Cutaquig®) is now accessible in the AAAAI Annual Meeting Virtual Poster Hall. The study by authors Richard...
Recent Comments